Aducanumab for Alzheimer ' s disease: expediting approval and delaying science

At the beginning of this month of June, the Food and Drug Administration (FDA) announced its decision to grant marketing authorisation to the monoclonal antibody aducanumab, the first treatment option targeting and affecting the underlying disease process of Alzheimer ' s disease, according to the press release of the medicines regulatory agency of the USA. What should have been a source of joy and recognition of the success of basic and clinical sciences, however, resulted in a bitter dispute in the scientific community, that ended up in the resignation of three of the experts who had participated in the committee that advised the agency on the safety and efficacy of this new drug.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news